Abraham Silji
Known title: Chief Digital & Trans OfficerCIK: 0001733001
Associated companies
Transaction History
| WST | ▲ Buy | Option Exercise | 458 | $0 | 10/29/2024 | View on chart |
| WST | ▼ Sell | Tax Withholding | 180 | $57K | 10/29/2024 | View on chart |
| WST | ▼ Sell | Open Market | 1,800 | $595K | 6/12/2024 | View on chart |
| WST | ▲ Buy | Option Exercise | 7,012 | $1.2M | 2/23/2024 | View on chart |
| WST | ▼ Sell | Open Market | 7,012 | $2.6M | 2/23/2024 | View on chart |
| WST | ▲ Buy | Grant | 646 | $0 | 2/20/2024 | View on chart |
| WST | ▲ Buy | Option Exercise | 8,160 | $836K | 8/8/2023 | View on chart |
| WST | ▼ Sell | Open Market | 6 | $2K | 8/8/2023 | View on chart |
| WST | ▼ Sell | Open Market | 8,154 | $3.2M | 8/8/2023 | View on chart |
| WST | ▲ Buy | Option Exercise | 8,020 | $692K | 5/1/2023 | View on chart |
| WST | ▼ Sell | Open Market | 7,371 | $2.7M | 5/1/2023 | View on chart |
| WST | ▼ Sell | Open Market | 649 | $238K | 5/1/2023 | View on chart |
| WST | ▼ Sell | Open Market | 1,500 | $484K | 3/9/2023 | View on chart |
| WST | ▲ Buy | Grant | 234 | $74K | 3/1/2023 | View on chart |
| WST | ▲ Buy | Grant | 2,274 | $697K | 2/21/2023 | View on chart |
| WST | ▼ Sell | Open Market | 5,374 | $1.8M | 8/1/2022 | View on chart |
| WST | ▲ Buy | Grant | 2,498 | $922K | 2/22/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
West Pharmaceutical Services noted in analyst upgrade and market rally
West Pharmaceutical Services has risen about 36% year-to-date, drawing attention in recent market round-ups. TD Cowen kept its positive stance and lifted its price target to $420, citing the company's performance. The stock also appeared in CNBC’s final‑trade segment and in a dividend‑growth stock list, highlighting investor interest.
West Pharmaceutical Services noted in analyst upgrade and market rally. West Pharmaceutical Services has risen about 36% year-to-date, drawing attention in recent market round-ups. TD Cowen kept its positive stance and lifted its price target to $420, citing the company's performance. The stock also appeared in CNBC’s final‑trade segment and in a dividend‑growth stock list, highlighting investor interest.